November 4, 2026
Centene up 10%, HCA up nearly 9%. The sector priced in a blue wave. Now comes the harder question.
Democrats flipped both chambers Tuesday night, projecting at least 258 House seats and seven Senate pickups. By Wednesday morning, the trade was already on. Centene surged more than 10%. HCA Healthcare jumped nearly 9%. Tenet Healthcare gained over 8%. Molina and Universal Health Services moved in the same direction. The market read the results fast, and it read them correctly, at least in the first 24 hours.
Bigger than Nvidia? Louis Navellier thinks so.
In 2016, Louis Navellier recommended Nvidia at $2.51 – split-adjusted. It went up 44,000%. He also called Apple before a 36,000% rise and Microsoft before a 60,800% climb. Now he says a new AI device coming online in Tennessee is the setup for the biggest call of his career.
He’s agreed to reveal the stock at the center of it – down to the ticker – for free.
The core thesis driving all of it is Medicaid. The Trump administration’s One Big Beautiful Bill included provisions expected to reduce Medicaid enrollment and constrain state-directed payments to hospitals. Analysts at J.P. Morgan and Jefferies flagged that a Democratic Congress could delay or block implementation of those cuts, which is exactly what the market priced Wednesday. Hospitals with heavy Medicaid exposure, specifically HCA, Tenet, Community Health Systems, and Acadia Healthcare, are the direct beneficiaries of that delay trade. No legislation needs to pass. Gridlock is enough.
What Actually Changes
Wolfe Research’s Tobin Marcus told CNBC that healthcare will be Democrats’ biggest legislative focus, specifically ACA premium subsidy restoration and unwinding parts of the Medicaid reforms. The filibuster is the wall. Democrats need 60 Senate votes to advance most legislation, and they don’t have it. That means no clean ACA bill reaches Trump’s desk, and even if one did, Trump has already said he may veto a subsidy extension. What Democrats can do is use committee oversight, budget process leverage, and appropriations fights to slow implementation of cuts already on the books.
They Proved It Worked in ’76. Then Buried It.
In 1976, Chevron tapped an energy source powerful enough to run a city. No fuel costs. No supply chain. Then they killed it. Unocal and Texaco did the same.
Now one company has spent sixty years perfecting what Big Oil refused to touch. Google locked in a 15-year contract. Bill Gates wrote a $100 million check.
On November 17th, Washington hands it an edge no other energy source gets.
That is a meaningful distinction for traders. The hospital and managed care rally is not a policy victory trade. It is a delay trade. The cuts exist. They are not repealed. Democrats in both chambers simply make them harder to implement on the original timeline. For Centene, Molina, and other Medicaid-heavy insurers, that timeline extension is worth real earnings per share. For hospital operators already absorbing uncompensated care pressure, it matters.
The Pharma Read Is More Complicated
Drug stocks are a different conversation. Merck and AbbVie both ran 12-14% in the three months heading into the election, which looks counterintuitive given that Democrats typically push harder on pricing than Republicans. The explanation from analysts at Leerink Partners and RBC Capital Markets is straightforward: Democrats have bigger priorities than drug pricing, and the IRA’s Medicare negotiation program already expands automatically each year without any new legislation required. The number of drugs subject to negotiation grows on its own. Democrats don’t need to touch it to claim credit.
Where pharma does face real exposure is on PBM oversight. The Consolidated Appropriations Act of 2026, signed in February, requires PBMs to pass 100% of rebates directly to plan sponsors and bans spread pricing in Medicare Part D starting in 2028. A Democratic Congress is likely to sharpen enforcement, add transparency requirements, and push to extend those rules into the commercial employer market. That is structural pressure on Optum Rx, CVS Caremark, and Express Scripts, and by extension on UnitedHealth and CVS Health, whose PBM operations generate significant margin.
He Called Black Monday. He Called the ’95 Tech Boom. He Called the 2009 Bottom. Now He’s Back.
Each time, Dr. Mark Skousen went against the crowd. Each time, the people who listened got a head start. Now “America’s Economist” is out with his boldest call in years.
Where the Trade Goes From Here
The sector has already moved. The S&P 500 healthcare sector was up roughly 20% in 2026 heading into Tuesday, and analysts at Axios and Argent Capital noted that some of that run reflected pre-positioning ahead of the election. Wednesday’s gap higher in hospital names adds to a move that began in September. The question now is not whether the trade worked. It is whether it has room left.
Tenet Healthcare is up over 38% year-to-date and already prices in a recovery story. Universal Health Services, still down nearly 12% on the year despite Wednesday’s bounce, offers a different entry. Acadia Healthcare, named specifically by Jefferies as a beneficiary of Democratic Medicaid protection, is the more speculative version of the same thesis. The delay trade has legs as long as implementation of OBBBA Medicaid provisions stays contested, which, in a divided government with 60-vote Senate math, it will.
- Stocks to watch on the hospital delay trade: UHS, ACHC, CYH. Tenet and HCA have already moved significantly.
- PBM pressure is structural, not cyclical. Watch CVS Health and UnitedHealth for commentary on enforcement risk in coming quarters.
- ACA subsidy restoration requires 60 Senate votes. Democrats don’t have them. Price the gridlock, not the legislation.
- Medicare negotiation expands automatically under the IRA. No Democratic bill needed. Biopharma risk here is lower than headlines suggest.
- Monitor Trump’s response. Jefferies noted he has signaled willingness to work with a Democratic Congress, which opens a narrower path to bipartisan PBM and hospital measures.
